Infliximab Level Between Venous and Capillary Blood Using Novel Device Strongly Correlate in Paediatric Inflammatory Bowel Disease Patients.
Journal
Journal of pediatric gastroenterology and nutrition
ISSN: 1536-4801
Titre abrégé: J Pediatr Gastroenterol Nutr
Pays: United States
ID NLM: 8211545
Informations de publication
Date de publication:
01 01 2021
01 01 2021
Historique:
pubmed:
18
8
2020
medline:
22
6
2021
entrez:
18
8
2020
Statut:
ppublish
Résumé
Blood to measure infliximab (IFX) levels is typically obtained with venipuncture. Dried blood sampling (DBS), using capillary blood obtained from a finger prick, would be an alternative to measure IFX blood levels while being more patient friendly. The aim of this study is to compare IFX blood level measured by venipuncture versus DBS in patients with paediatric inflammatory bowel disease (PIBD) to assure accuracy. A prospective clinical pilot study was performed in patients with PIBD. Before IFX infusion, blood was collected simultaneously through venipuncture and DBS from a finger prick, using Mitratips (Neoteryx). All IFX concentrations were measured by an enzyme-linked immunosorbent assay. The Bland-Altman analysis was used to measure limits of agreement. The interrater reliability was measured with the interclass correlation coefficient and Cohen kappa. To calculate Cohen kappa, IFX levels were categorized into 3 groups; low <5 μg/mL, adequate 5 to 10 μg/mL, and high >10 μg/mL. Twenty patients were included. Median age was 12.1 year (interquartile range 8-16 year). The mean difference between the 2 methods was -0.14 as calculated with Bland-Altman plot. The limits of agreement were between -1.39 and 1.12. The interclass correlation coefficient was with 0.998 excellent. The Cohen kappa between 3 IFX level categories was strong K = 0.911 (P = 0.0001). There was a strong correlation between venous IFX serum levels and DBS (r = 0.991, P = 0.0001) in the included patients. This is the first study in patients with PIBD to show that bloodspot technology is a patient friendly alternative method to measure IFX blood levels in PIBD.
Identifiants
pubmed: 32804907
pii: 00005176-202101000-00014
doi: 10.1097/MPG.0000000000002906
doi:
Substances chimiques
Gastrointestinal Agents
0
Infliximab
B72HH48FLU
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
56-60Informations de copyright
Copyright © 2020 by European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition.
Références
Turner D, Ruemmele FM, Orlanski-Meyer E, et al. Management of paediatric ulcerative colitis, part 1: ambulatory care-an evidence-based guideline from European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018; 67:257–291.
Ruemmele FM, Veres G, Kolho KL, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. J Crohns Colitis 2014; 8:1179–1207.
Corica D, Romano C. Biological therapy in pediatric inflammatory bowel disease: a systematic review. J Clin Gastroenterol 2017; 51:100–110.
Winter DA, Joosse ME, De Wildt SN, et al. Pharmacokinetics, pharmacodynamics and immunogenicity of infliximab in paediatric inflammatory bowel disease; a systematic review and revised dosing considerations. J Pediatr Gastroenterol Nutr 2020; 70:763–776.
Singh N, Rosenthal CJ, Melmed GY, et al. Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 2014; 20:1708–1713.
Kennedy NA, Heap GA, Green HD, et al. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol 2019; 4:341–353.
Van Hoeve K, Dreesen E, Hoffman I, et al. Higher infliximab trough levels are associated with better outcome in paediatric patients with inflammatory bowel disease. J Crohns Colitis 2018; 12:1316–1325.
Carman N, Mack DR. Benchimol EI therapeutic drug monitoring in pediatric inflammatory bowel disease. Curr Gastroenterol Rep 2018; 20:18.
Papamichael K, Vajravelu RK, Vaughn BP, et al. Proactive infliximab monitoring following reactive testing is associated with better clinical outcomes than reactive testing alone in patients with inflammatory bowel disease. J Crohns Colitis 2018; 12:804–810.
Berends SE, D’Haens G, Schaap T, et al. Dried blood samples can support monitoring of infliximab concentrations in patients with inflammatory bowel disease: a clinical validation. Br J Clin Pharmacol 2019; 85:1544–1551.
Kneepkens EL, Pouw MF, Wolbink GJ, et al. Dried blood spots from finger prick facilitate therapeutic drug monitoring of adalimumab and anti-adalimumab in patients with inflammatory diseases. Br J Clin Pharmacol 2017; 83:2474–2484.
Stein R, Lee D, Leonard MB, et al. Serum infliximab, antidrug antibodies, and tumor necrosis factor predict sustained response in pediatric Crohn's disease. Inflamm Bowel Dis 2016; 22:1370–1377.
Lega S, Phan BL, Rosenthal CJ, et al. Proactively optimized infliximab monotherapy is as effective as combination therapy in IBD. Inflamm Bowel Dis 2019; 25:134–141.
Reinink AR. A pharmacokinetic rationale for proactive therapeutic drug monitoring of anti-TNF drugs. Am J Gastroenterol 2017; 112:1892–1893.
Spooner N, Denniff P, Michielsen L, et al. A device for dried blood microsampling in quantitative bioanalysis: overcoming the issues associated blood hematocrit. Bioanalysis 2015; 7:653–659.
Vande Casteele N, Buurman DJ, Sturkenboom MG, et al. Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays. Aliment Pharmacol Ther 2012; 36:765–771.
Giavarina D. Understanding Bland Altman analysis. Biochem Med (Zagreb) 2015; 25:141–151.
Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1:307–310.
Lu MJ, Zhong WH, Liu YX, et al. Sample size for assessing agreement between two methods of measurement by Bland-Altman method. Int J Biostat 2016; 12:
Piester T, Frymoyer A, Christofferson M, et al. A mobile infliximab dosing calculator for therapy optimization in inflammatory bowel disease. Inflamm Bowel Dis 2018; 24:227–234.
Curci D, Lucafo M, Cifu A, et al. Determination of serum infliximab concentration by point-of-care devices in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2019; 69:474–479.
Martial LC, Aarnoutse RE, Schreuder MF, et al. Cost evaluation of dried blood spot home sampling as compared to conventional sampling for therapeutic drug monitoring in children. PLoS One 2016; 11:e0167433.